Abstract: One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.

Abstract: One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.

Abstract: One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.

Abstract: One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.

Abstract: Polypeptides are susceptible to denaturation or enzymatic degradation in the blood, liver or kidney. Due to the low stability of some polypeptides, it has been required to administer polypeptide drugs in a sustained frequency to a subject in order to maintain an effective plasma concentration of the active substance. Furthermore, pharmaceutical compositions of therapeutic peptides preferably have a shelf-life of several years in order to be suitable for common use. However, peptide compositions are inherently unstable due to sensitivity towards chemical and physical degradation. In part, the invention provides SAP variant proteins, compositions, pharmaceutical preparations and formulations having a prolonged in vivo half-life, prolonged shelf-life, or rather increased in vitro stability, or increased manufacturing efficiency compared to human SAP. Advantages of increased plasma half-life include, but are not limited to, reducing the amount and/or frequency of dosing.

Abstract: Electrical interfaces, addressing schemes, and command protocols allow for communications with memory modules in computing devices such as imaging and printing devices. Memory modules may be assigned an address through a set of discrete voltages. One, multiple, or all of the memory modules may be addressed with a single command, which may be an increment counter command, a write command, a punch out bit field, or a cryptographic command. The commands may be transmitted using a broadcast scheme or a split transaction scheme. The status of the memory modules may be determined by sampling a single signal that may be at a low, high, or intermediate voltage level.

Abstract: One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.

Abstract: Electrical interfaces, addressing schemes, and command protocols allow for communications with memory modules in computing devices such as imaging and printing devices. Memory modules may be assigned an address through a set of discrete voltages. One, multiple, or all of the memory modules may be addressed with a single command, which may be an increment counter command, a write command, a punch out bit field, or a cryptographic command. The commands may be transmitted using a broadcast scheme or a split transaction scheme. The status of the memory modules may be determined by sampling a single signal that may be at a low, high, or intermediate voltage level.

Abstract: Methods and apparatus teach wear leveling non-volatile memory and secure erasure of data. A computing device receives data to be stored. The data is encrypted, including generation of encryption/decryption key(s). The key(s) are stored in either non-volatile or volatile memory according to a plurality of classification schemes. In a first scheme, key(s) are stored in non-volatile memory and will be retained in the event of a power cycle of the computing device. Otherwise, key(s) stored in volatile memory will be lost upon a power cycle. Upon issuance of a key destruction command, key(s) in the non-volatile memory are sanitized or erased, but the underlying encrypted data need not be erased since no key(s) exist that can recover original content. These techniques limit erasure commands to the non-volatile memory which prolongs its service life. Further embodiments note techniques in imaging devices conducting imaging operations, such as printing or scanning.

Abstract: Methods and apparatus teach wear leveling non-volatile memory and secure erasure of data. A computing device receives data to be stored. The data is encrypted, including generation of encryption/decryption key(s). The key(s) are stored in either non-volatile or volatile memory according to a plurality of classification schemes. In a first scheme, key(s) are stored in non-volatile memory and will be retained in the event of a power cycle of the computing device. Otherwise, key(s) stored in volatile memory will be lost upon a power cycle. Upon issuance of a key destruction command, key(s) in the non-volatile memory are sanitized or erased, but the underlying encrypted data need not be erased since no key(s) exist that can recover original content. These techniques limit erasure commands to the non-volatile memory which prolongs its service life. Further embodiments note techniques in imaging devices conducting operations, such as printing or scanning.

Abstract: Methods and apparatus teach wear leveling non-volatile memory and secure erasure of data. A computing device receives data to be stored. The data is encrypted, including generation of encryption/decryption key(s). The key(s) are stored in either non-volatile or volatile memory according to a plurality of classification schemes. In a first scheme, key(s) are stored in non-volatile memory and will be retained in the event of a power cycle of the computing device. Otherwise, key(s) stored in volatile memory will be lost upon a power cycle. Upon issuance of a key destruction command, key(s) in the non-volatile memory are sanitized or erased, but the underlying encrypted data need not be erased since no key(s) exist that can recover original content. These techniques limit erasure commands to the non-volatile memory which prolongs its service life. Further embodiments note techniques in imaging devices conducting imaging operations, such as printing or scanning.

Abstract: The present invention provides conjugates between peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.

Abstract: A print release environment includes a print server and pluralities of imaging devices. A user of a computing device sends to the print server a current print job for imaging operations. The print server analyzes metrics of the current print job relative to prior print jobs of the same user. Before the user makes a claim to pick up the current print job from a specific one of the imaging devices, the print server predicts when and where the user will likely make their claim. Techniques note actions to speed processing based on the predictions.

Abstract: Functionalized pentraxin-2 (PTX-2) protomers and functionalized PTX-2 pentamers, methods for preparing functionalized PTX-2 protomers and functionalized PTX-2 pentamers, pharmaceutical compositions including functionalized PTX-2 pentamers, and methods for using the same are described herein.

Abstract: The present invention provides methods of refolding mammalian glycosyltransferases that have been produced in bacterial cells, and methods to use such refolded glycosyltransferases, including glycosyltransferase mutants that have enhanced ability to be refolded. The invention also provides methods of refolding more than one glycosyltransferase in a single vessel, methods to use such refolded glycosyltransferases, and reaction mixtures comprising the refolded glycosyltransferases.

Abstract: Electrical interfaces, addressing schemes, and command protocols allow for communications with memory modules in computing devices such as imaging and printing devices. Memory modules may be assigned an address through a set of discrete voltages. One, multiple, or all of the memory modules may be addressed with a single command, which may be an increment counter command, a write command, a punch out bit field, or a cryptographic command. The commands may be transmitted using a broadcast scheme or a split transaction scheme. The status of the memory modules may be determined by sampling a single signal that may be at a low, high, or intermediate voltage level.

Abstract: Electrical interfaces, addressing schemes, and command protocols allow for communications with memory modules in computing devices such as imaging and printing devices. Memory modules may be assigned an address through a set of discrete voltages. One, multiple, or all of the memory modules may be addressed with a single command, which may be an increment counter command, a write command, a punch out bit field, or a cryptographic command. The commands may be transmitted using a broadcast scheme or a split transaction scheme. The status of the memory modules may be determined by sampling a single signal that may be at a low, high, or intermediate voltage level.

Abstract: The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided.

Abstract: Polypeptides are susceptible to denaturation or enzymatic degradation in the blood, liver or kidney. Due to the low stability of some polypeptides, it has been required to administer polypeptide drugs in a sustained frequency to a subject in order to maintain an effective plasma concentration of the active substance. Furthermore, pharmaceutical compositions of therapeutic peptides preferably have a shelf-life of several years in order to be suitable for common use. However, peptide compositions are inherently unstable due to sensitivity towards chemical and physical degradation. In part, the invention provides SAP variant proteins, compositions, pharmaceutical preparations and formulations having a prolonged in vivo half-life, prolonged shelf-life, or rather increased in vitro stability, or increased manufacturing efficiency compared to human SAP. Advantages of increased plasma half-life include, but are not limited to, reducing the amount and/or frequency of dosing.

Abstract: Electrical interfaces, addressing schemes, and command protocols allow for communications with memory modules in computing devices such as imaging and printing devices. Memory modules may be assigned an address through a set of discrete voltages. One, multiple, or all of the memory modules may be addressed with a single command, which may be an increment counter command, a write command, a punch out bit field, or a cryptographic command. The commands may be transmitted using a broadcast scheme or a split transaction scheme. The status of the memory modules may be determined by sampling a single signal that may be at a low, high, or intermediate voltage level.